News about "Bristol Myers Squibb"

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Evotec has reported advancement in its preclinical neuroscience collaboration with Bristol Myers Squibb, securing a payment of USD 25 Million to support the continued development of jointly pursued therapeutic programmes.

Bristol Myers Squibb | 28/10/2025 | By Dineshwori

SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ADC at ESMO 2025

Iza-bren, a potentially first-in-class EGFR x HER3 bispecific Antibody-Drug Conjugate (ADC), is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive licence agreement in territories outside of Mainland China.

Bristol Myers Squibb | 21/10/2025 | By Dineshwori

Alembic Pharmaceuticals Gets USFDA Nod for Triamcinolone Acetonide Injection

The approved ANDA, Triamcinolone Acetonide Injection, is therapeutically equivalent to the Reference Listed Drug (RLD) product, Kenalog-40 Injectable Suspension, of Bristol-Myers Squibb company.

Bristol-Myers Squibb | 21/10/2025 | By Dineshwori

Bristol Myers Squibb Acquires Orbital Therapeutics

The acquisition of Orbital Therapeutics by Bristol Myers Squibb includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogramme cells in vivo with potential best-in-class profile for autoimmune diseases.

Bristol Myers Squibb | 13/10/2025 | By Dineshwori

Lupin Secures US FDA Approval for Lenalidomide Capsules

The approved Lenalidomide Capsules, bioequivalent to Revlimid by Bristol-Myers Squibb, will be produced at Lupin’s Pithampur site in India.

Bristol-Myers Squibb | 17/09/2025 | By Dineshwori |  164

Alkermes appoints Joshua Reed as CFO

The newly-appointed CFO at Alkermes, Joshua Reed, brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. Most recently, he served as CFO of Omega Therapeutics.

Bristol Myers Squibb | 13/09/2025 | By Dineshwori

Four Drugs in Race for First Bispecific ADC Approval: GlobalData

With 21 global approvals, ADCs generated USD 13.6 billion in 2024. BsADCs represent further opportunities in this field, by leveraging bi-specific antibodies that simultaneously bind two distinct targets.

Bristol Myers Squibb | 02/09/2025 | By Dineshwori |  153

Biopharma Firms See 5.7 Percent Market Cap Drop in Q2 2025: Globaldata

Twenty biopharmaceutical companies have reported a 5.7 percent quarter-on-quarter (QoQ) downturn in their combined market capitalisation from USD 3.9 trillion on 31 March, 2025 to USD 3.7 trillion on 30 June, 2025.

Bristol Myers Squibb | 01/09/2025 | By Dineshwori |  115

Scenic Biotech Partners with Alnylam to Advance RNAi Therapeutics Using Cell-Seq Platform

This collaboration represents Scenic Biotech’s third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb. <br />

Bristol Myers Squibb | 26/08/2025 | By Dineshwori |  185

Evotec Announces Progress in its Collaboration with Bristol Myers Squibb

Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases where there remains a significant unmet medical need for therapies that slow down or reverse disease progression.

Bristol Myers Squibb | 12/08/2024 | By Aishwarya |  370